688 related articles for article (PubMed ID: 28321124)
1. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
2. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
Willmann M; Sadovnik I; Eisenwort G; Entner M; Bernthaler T; Stefanzl G; Hadzijusufovic E; Berger D; Herrmann H; Hoermann G; Valent P; Rülicke T
Exp Hematol; 2018 Jan; 57():50-59.e6. PubMed ID: 29031704
[TBL] [Abstract][Full Text] [Related]
5. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Nguyen T; Dai Y; Attkisson E; Kramer L; Jordan N; Nguyen N; Kolluri N; Muschen M; Grant S
Clin Cancer Res; 2011 May; 17(10):3219-32. PubMed ID: 21474579
[TBL] [Abstract][Full Text] [Related]
7. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
Zhou Z; Liu T; Zhang J
Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
[TBL] [Abstract][Full Text] [Related]
8. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
[TBL] [Abstract][Full Text] [Related]
9. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
[TBL] [Abstract][Full Text] [Related]
10. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
Carter BZ; Mak DH; Shi Y; Schober WD; Wang RY; Konopleva M; Koller E; Dean NM; Andreeff M
Cell Cycle; 2006 Oct; 5(19):2223-9. PubMed ID: 16969080
[TBL] [Abstract][Full Text] [Related]
11. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
12. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
15. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
Jamieson CH; Ailles LE; Dylla SJ; Muijtjens M; Jones C; Zehnder JL; Gotlib J; Li K; Manz MG; Keating A; Sawyers CL; Weissman IL
N Engl J Med; 2004 Aug; 351(7):657-67. PubMed ID: 15306667
[TBL] [Abstract][Full Text] [Related]
17. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M
Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552
[TBL] [Abstract][Full Text] [Related]
19. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]